Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized amikacin for ventilator-associated gram-negative pneumonia in VA-ECMO patients (NAVAP-ECMO)
2023-509722-22-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of amikacin in Gram-negative pneumonia, ventilator-associated pneumonia (VAP) and pneumonia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Bacterial eradication rate at day 5. Planned start Jun 2024; status: authorised.
02
Drugs
amikacin
03
Conditions
Gram-negative pneumoniaventilator-associated pneumonia (VAP)pneumonia
Beyond the preview
Go deeper on 2023-509722-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509722-22-00.